Paolo Pozzilli

Summary

Affiliation: University Campus Bio-Medico
Country: Italy

Publications

  1. ncbi Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?
    Andrea Palermo
    University Campus Bio Medico, Department Endocrinology and Diabetes, Via Alvaro del Portillo, 21, 00128 Rome, Italy 39 06 225419184 39 06 22541456
    Expert Opin Biol Ther 12:767-72. 2012
  2. ncbi Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Via Alvaro del Portillo, 21, 00128 Rome, Italy
    Nat Rev Endocrinol 8:78-80. 2012
  3. ncbi Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes
    Ilaria Barchetta
    Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy
    BMC Med 9:85. 2011
  4. ncbi Double diabetes: a mixture of type 1 and type 2 diabetes in youth
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Endocr Dev 14:151-66. 2009
  5. ncbi New prospects for immunotherapy at diagnosis of type 1 diabetes
    Paolo Pozzilli
    University Campus Bio Medico, Rome, Italy
    Diabetes Metab Res Rev 25:299-301. 2009
  6. ncbi Double or hybrid diabetes associated with an increase in type 1 and type 2 diabetes in children and youths
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Pediatr Diabetes 8:88-95. 2007
  7. ncbi A new expression of diabetes: double diabetes
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, Campus Bio Medico University, Via E Longoni 83, 00155 Rome, Italy
    Trends Endocrinol Metab 18:52-7. 2007
  8. ncbi Immunomodulation for the prevention of SPIDDM and LADA
    P Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Via E Longoni 83, 00155 Rome, Italy
    Ann N Y Acad Sci 1079:90-8. 2006
  9. ncbi Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes
    P Pozzilli
    Dept Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Horm Metab Res 37:680-3. 2005
  10. ncbi A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8)
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, Università Campus Bio Medico, Rome, Italy
    Diabetes Technol Ther 5:965-74. 2003

Detail Information

Publications52

  1. ncbi Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?
    Andrea Palermo
    University Campus Bio Medico, Department Endocrinology and Diabetes, Via Alvaro del Portillo, 21, 00128 Rome, Italy 39 06 225419184 39 06 22541456
    Expert Opin Biol Ther 12:767-72. 2012
    ....
  2. ncbi Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Via Alvaro del Portillo, 21, 00128 Rome, Italy
    Nat Rev Endocrinol 8:78-80. 2012
    ..Patient phenotyping should be performed for the implementation of tailored therapies, especially taking into account the age at which the disease is diagnosed...
  3. ncbi Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes
    Ilaria Barchetta
    Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy
    BMC Med 9:85. 2011
    ..Aim of our study was to test the hypothesis of a direct association between hypovitaminosis D and the presence of NAFLD in subjects with various degree of insulin-resistance and related metabolic disorders...
  4. ncbi Double diabetes: a mixture of type 1 and type 2 diabetes in youth
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Endocr Dev 14:151-66. 2009
    ....
  5. ncbi New prospects for immunotherapy at diagnosis of type 1 diabetes
    Paolo Pozzilli
    University Campus Bio Medico, Rome, Italy
    Diabetes Metab Res Rev 25:299-301. 2009
    ..Here we outline the rationale of such interventions and future prospects in this area...
  6. ncbi Double or hybrid diabetes associated with an increase in type 1 and type 2 diabetes in children and youths
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Pediatr Diabetes 8:88-95. 2007
    ..In this review, we report recent findings on the increasing rates of all forms of diabetes in the young population, including unpublished data collected in Russia...
  7. ncbi A new expression of diabetes: double diabetes
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, Campus Bio Medico University, Via E Longoni 83, 00155 Rome, Italy
    Trends Endocrinol Metab 18:52-7. 2007
    ..However, recognition of double diabetes can pose problems. In most cases, a reduction in the 'autoimmune load' and an increase in the 'metabolic load' are helpful for attaining a correct diagnosis in a diabetic child...
  8. ncbi Immunomodulation for the prevention of SPIDDM and LADA
    P Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Via E Longoni 83, 00155 Rome, Italy
    Ann N Y Acad Sci 1079:90-8. 2006
    ..Response to therapy varies according to age and residual beta cell function at diagnosis of SPIDMM/LADA. Results in beta cell protection with different agents can also help to identify differences, if any, between SPIDMM and LADA...
  9. ncbi Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes
    P Pozzilli
    Dept Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Horm Metab Res 37:680-3. 2005
    ..The aim of this surveillance study was to measure levels of both 25-hydroxyvitamin D3 (25OHD3) and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes as compared to normal subjects...
  10. ncbi A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8)
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, Università Campus Bio Medico, Rome, Italy
    Diabetes Technol Ther 5:965-74. 2003
    ..Both types of intensive insulin therapy combined with NA are able to preserve C-peptide secretion or even increase baseline levels for up to 2 years after diagnosis...
  11. ncbi Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, Università Campus Bio Medico, Via Álvaro del Portillo 21 00128, Rome, Italy
    Curr Pharm Des 17:3224-8. 2011
    ..These approaches are currently being tested in international multicenter trials and all of them have a very similar outcome in terms of a beneficial effect on beta cells...
  12. ncbi No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial
    Carla Bizzarri
    Department of Endocrinology and Diabetes, Bambino Gesu Children s Hospital, Rome, Italy
    Diabetes Care 33:1962-3. 2010
    ..We investigated whether supplementation of the active form of vitamin D (calcitriol) in recent-onset type 1 diabetes can protect beta-cell function evaluated by C-peptide and improve glycemic control assessed by A1C and insulin requirement...
  13. ncbi C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study
    Raffaella Buzzetti
    Department of Medicina Interna e Specialità Mediche, Division of Diabetes, University Sapienza, Rome, Italy
    Diabetes 60:3067-72. 2011
    ..To investigate whether lower risk HLA class II genotypes would influence the efficacy of DiaPep277 therapy in protecting ?-cell function evaluated by C-peptide secretion in recent-onset type 1 diabetic subjects...
  14. ncbi The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual beta-cell function and worse metabolic control
    Antonio Petrone
    Endocrinology, Department of Clinical Science, University Sapienza, Polo Pontino, Rome, Italy
    Diabetes Care 31:1214-8. 2008
    ....
  15. ncbi Menarche in type 1 diabetes is still delayed despite good metabolic control
    Antonio Picardi
    Area di Endocrinologia e Diabetologia, Università Campus Bio Medico, Rome, Italy
    Fertil Steril 90:1875-7. 2008
    ..Previous studies on the appearance of menarche showed that the mean age of onset of menarche is delayed in girls affected by T1D compared with normal girls...
  16. ncbi Westernization of the Filipino population resident in Rome: obesity, diabetes and hypertension
    Umberto Vespasiani Gentilucci
    Internal Medicine and Hepatology, Centre of Interdisciplinary Research, Rome, Italy
    Diabetes Metab Res Rev 24:364-70. 2008
    ..Aims of the present study were to examine the anthropometrical and metabolic characteristics of the Filipino population migrant to the Southern European city of Rome, Italy...
  17. ncbi A novel insulin unit calculator for the management of type 1 diabetes
    Anna Rita Maurizi
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Diabetes Technol Ther 13:425-8. 2011
    ..Cambridge, UK) is a new tool for the administration of insulin dose before each meal. The aim of this study was to evaluate the efficacy of Calsulin on metabolic control in T1D patients undergoing intensive insulin therapy...
  18. ncbi The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Diabetes Metab Res Rev 26:239-44. 2010
    ..Based on these parameters, physicians can select the therapeutic strategy with minimum risk and maximum benefit for each individual...
  19. ncbi The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3
    Antonio Petrone
    Department of Clinical Science, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Rome, Italy
    Diabetes Care 31:534-8. 2008
    ..The aim of the present study was to evaluate whether the phenotypic heterogeneity of adult-onset autoimmune diabetes based on the GADA titer is associated with the PTPN22 C1858T polymorphism...
  20. ncbi Unexpectedly high rates of obesity and dysglycemia among villagers in Cameroon
    Nicola Napoli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Diabetes Metab Res Rev 26:10-2. 2010
    ..From our preliminary study, we raise the possibility that the environmental elements that are driving the pandemic of obesity and diabetes in sub-Saharan Africa are far more complex than heretofore appreciated...
  21. ncbi Continuous subcutaneous insulin infusion (CSII) in inpatient setting: unmet needs and the proposal of a CSII unit
    Lelio Morviducci
    Diabetes Unit, San Camillo Forlanini Hospital, Rome, Italy
    Diabetes Technol Ther 13:1071-4. 2011
    ..We suggest that a CSII unit should be activated inside the hospital, in order to increase compliance with required procedures and to properly address the unmet needs of CSII in inpatient setting...
  22. ncbi Biokinetics of buccal spray insulin in patients with type 1 diabetes
    Paolo Pozzilli
    Department of Endocrinoplogy and Diabetes, University Campus Bio Medico, Rome, Italy
    Metabolism 54:930-4. 2005
    ..To evaluate the metabolic effect of buccal spray insulin compared with subcutaneous regular insulin in patients with type 1 diabetes...
  23. ncbi Blue eyes as a risk factor for type 1 diabetes
    Enrico Di Stasio
    Institute of Biochemistry and Clinical Biochemistry, Catholic University of Sacred Hearth, Rome, Italy
    Diabetes Metab Res Rev 27:609-13. 2011
    ..We determined whether iris colour and skin pigmentation are risk factors in a Caucasian population living in two Mediterranean regions located at the same latitude with higher ultraviolet B irradiance, but with different T1D incidence...
  24. ncbi DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes
    Dario Tuccinardi
    University Campus Bio Medico, Via Alvaro del Portillo, 21 00128, Rome, Italy
    Expert Opin Biol Ther 11:1233-40. 2011
    ..The results of two large Phase III trials will tell us whether this therapy may change our current approach to treating T1D patients at diagnosis...
  25. ncbi Quality of diet and potential renal acid load as risk factors for reduced bone density in elderly women
    Claudio Pedone
    Area di Geriatria, Università Campus Biomedico Roma, Italy Fondazione Alberto Sordi Onlus Roma, Italy
    Bone 46:1063-7. 2010
    ..Bone mineral density (BMD) may be influenced by the general dietary pattern and the potential renal acid load (PRAL)...
  26. ncbi Challenges in developing endpoints for type 1 diabetes intervention studies
    Simona Cernea
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Diabetes Metab Res Rev 25:694-704. 2009
    ..This report summarizes the conclusions of the D-Cure workshop of international experts held in Barcelona in April 2007 and the current recommendations and updates in the field...
  27. ncbi IL12B polymorphism and type 1 diabetes in the Italian population: a case-control study
    Lorenza Nisticò
    Institute of Cell Biology, CNR, Campus Buzzati Traverso, Monterotondo, Rome, Italy
    Diabetes 51:1649-50. 2002
    ..We analyzed the same polymorphism in 470 Italian type 1 diabetic patients and 544 matched control subjects and found no evidence of association with the disease...
  28. ncbi Review of clinical trials: update on oral insulin spray formulation
    Paolo Pozzilli
    Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy
    Diabetes Obes Metab 12:91-6. 2010
    ..This article provides an overview of the safety profile and proposed mechanism of action of this insulin formulation and presents findings from trials which studied its effects in subjects with T1DM and T2DM...
  29. ncbi TNF-alpha and growth hormone resistance in patients with chronic liver disease
    Antonio Picardi
    Laboratory of Internal Medicine and Hepatology, Interdisciplinary Center for Biomedical Research CIR, University Campus Bio Medico, Rome, Italy
    J Interferon Cytokine Res 23:229-35. 2003
    ..In addition, GH resistance is present in CLD from the early stages. These results could begin new therapeutic lines of attack in the management of CLD...
  30. ncbi Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis
    Umberto Vespasiani Gentilucci
    Interdisciplinary Center for Biomedical Research (CIR, Laboratory of Internal Medicine and Hepatology, University Campus Bio-Medico, Rome, Italy
    Acta Biomed 75:69-73. 2004
    ..The patient was ultimately treated for sarcoidosis and after one year of specific therapy has completely recovered without recurrence of cardiac or respiratory symptoms up to date...
  31. ncbi Physical exercise, public health and quality of life in diabetes
    Franco Fallucca
    University Sapienza, Rome, Italy
    Diabetes Metab Res Rev 25:S1-3. 2009
    ....
  32. ncbi Dietary pattern and bone density changes in elderly women: a longitudinal study
    Claudio Pedone
    Area di Geriatria, Universita Campus BioMedico, Rome, Italy
    J Am Coll Nutr 30:149-54. 2011
    ..Few data are available on the effect of the diet in general on bone health. The objective of this study was to identify dietary patterns and to evaluate the association between such patterns and bone mineral density (BMD) changes over time...
  33. ncbi A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes
    Dehuang Guo
    Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, Georgia 30912, USA
    Nat Genet 36:837-41. 2004
    ..5 times greater NF kappa B transcriptional activity and approximately 2 times greater expression of IL12B, an NF kappa B-dependent gene. These findings suggest a new pathway that may be implicated in the pathogenesis of T1D...
  34. ncbi Association of CTLA-4 variation with type I diabetes in Filipinos
    William Klitz
    School of Public Health, University of California, 140 Warren Hall, Berkeley, CA 94720 7360, USA
    Immunogenetics 54:310-3. 2002
    ..6, P=0.001), demonstrating that non- HLA loci, acting in concert with HLA, can play potent roles in modifying susceptibility to TID...
  35. ncbi beta-cell antigen-specific CD56(+) NKT cells from type 1 diabetic patients: autoaggressive effector T cells damage human CD56(+) beta cells by HLA-restricted and non-HLA-restricted pathways
    Dawei Ou
    Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, B C, Canada
    Hum Immunol 63:256-70. 2002
    ..These results suggest that CD56(+) NKT cells are aggressive cytotoxic cells to beta cells and that CD56 expression might be associated with the aggressiveness of effector T cells and the susceptibility of target cells...
  36. ncbi Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes
    Philip E Beales
    Department of Diabetes and Metabolism, St Bartholomew's Hospital, London, UK
    Diabetes Metab Res Rev 18:114-7. 2002
    ..Its use may be considered for trials designed to protect beta-cell function in humans, especially in patients with latent autoimmune diabetes of adults (LADA) and also for disease prevention...
  37. ncbi Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes
    Carla J Greenbaum
    TrialNet Publications, The Biostatistics Center, Rockville, Maryland, USA
    Diabetes Care 31:1966-71. 2008
    ..The Type 1 Diabetes TrialNet Research Group and the European C-peptide Trial (ECPT) Study Group conducted parallel randomized studies to compare the sensitivity, reproducibility, and tolerability of these procedures...
  38. ncbi Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults
    Sinead Brophy
    School of Medicine, Swansea University, Swansea SA2 8PP, UK
    Diabetes Care 31:439-41. 2008
    ..Latent autoimmune diabetes in adults is type 1 diabetes presenting as non-insulin dependent diabetes. One feature of the selection criteria is time independent of insulin treatment. We examine the validity of this criterion...
  39. ncbi Type 1 diabetes risk for human leukocyte antigen (HLA)-DR3 haplotypes depends on genotypic context: association of DPB1 and HLA class I loci among DR3- and DR4-matched Italian patients and controls
    Janelle A Noble
    Childrens Hospital Oakland Research Institute, Oakland, CA, USA
    Hum Immunol 69:291-300. 2008
    ..These data indicate that T1D risk conferred by the 8.1 haplotype is genotype dependent...
  40. ncbi The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention
    Paolo Pozzilli
    Diabetes Metab Res Rev 18:257-9. 2002
    ..DPT-1 has paved the way on how to proceed and new trials will be planned benefiting from such experience...
  41. ncbi C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001
    Jerry P Palmer
    Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes 53:250-64. 2004
    ..The development of therapies for addressing this important unmet clinical need will be facilitated by trials that are carefully designed with beta-cell function as determined by C-peptide measurement as the primary efficacy outcome...
  42. ncbi Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos
    Teodorica L Bugawan
    Roche Molecular Systems, Alameda, CA 94501, USA
    Am J Hum Genet 72:1505-14. 2003
    ..Our data suggest that the risk for T1D is determined, in part, by polymorphisms within the IL4R locus, including promoter and coding-sequence variants, and by specific combinations of genotypes at the IL4R and the IL4 and IL13 loci...
  43. ncbi Screening for type 1 diabetes genetic risk in newborns of continental Italy. Primary prevention (Prevefin Italy)--preliminary data
    Renata Lorini
    Dept. of Pediatrics, G. Gaslini Institute, Genoa, Italy
    Acta Biomed 76:31-5. 2005
  44. ncbi Glucose control in diabetes
    Cristina Valeri
    Department of Diabetes and Immunology, Queen Mary University, London, UK
    Diabetes Metab Res Rev 20:S1-8. 2004
    ....
  45. ncbi Diabetes incidence in 0- to 14-year age-group in Italy: a 10-year prospective study
    Flavia Carle
    Department of Pediatrics, Polytechnic University of Marche Via Corridoni, 11 I-60123 Ancona, Italy
    Diabetes Care 27:2790-6. 2004
    ..However, the rates are evenly increasing both in the mainland and Sardegna, suggesting that similar environmental factors are operating over populations that have different genetic backgrounds...
  46. ncbi Synergistic inhibition of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human pancreatic beta cells by Bcl-2 and X-linked inhibitor of apoptosis
    Dawei Ou
    Department of Pediatrics, University of British Columbia, British Columbia, Canada
    Hum Immunol 66:274-84. 2005
    ..These results indicate that Bcl-2 and XIAP synergistically inhibit TRAIL-mediated death pathways in human beta cells...
  47. ncbi Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow
    R David G Leslie
    Institute of Cell and Molecular Science, Queen Mary College, University of London, London E1 4NS, United Kingdom
    J Clin Endocrinol Metab 91:1654-9. 2006
    ..We looked at this entire range of forms of autoimmune diabetes as a spectrum of genetic and nongenetic environmental influences, diabetes-associated immune responses, and metabolic changes...
  48. ncbi Obesity in the Neolithic era: a Greek female figurine
    Helen Christopoulou-Aletra
    History of Medicine, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Obes Surg 16:1112-4. 2006
    ..In addition, the historical and social background of the Prehistoric period is taken into consideration, in an attempt to evaluate the characteristics of ancient feminine obesity and compare it to its modern definitions...
  49. ncbi Blood ketone bodies in patients with recent-onset type 1 diabetes (a multicenter study)
    Francesco Prisco
    Department of Pediatrics, Second University of Naples, Naples, Italy
    Pediatr Diabetes 7:223-8. 2006
    ..Further studies are needed to assess its use in the early detection and management of DKA...
  50. ncbi Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube et al
    Umberto Vespasiani Gentilucci
    Diabetes Care 29:2558-9; author reply 2559-60. 2006
  51. ncbi Immuno-intervention and preservation of beta-cell function in type 1 diabetes
    Paolo Pozzilli
    Diabetes Metab Res Rev 23:255-6. 2007
  52. ncbi Bather. Fernando Botero--Medellín 1932
    PieradePedrini Misani
    University of Rome La Sapienza, Italy
    J Endocrinol Invest 25:198. 2002